Shots:
The US FDA has approved Priorix for active immunization to treat measles, mumps, and rubella in patients aged ≥12mos.
Priorix’s safety was investigated in 6 clinical trials in 12151 patients (6,391 in the US) who received at least 1 dose of the vaccine. Priorix’s efficacy was established using immunogenicity data over comparator vaccine
Priorix can be administered as a first dose followed by a second one. The vaccine can also be administered as a second dose for individuals who have previously received the first dose of another MMR-containing vaccine. Priorix is currently licensed in 100+ countries globally including all EU countries, Canada, Australia, and New Zealand & has distributed ~800M doses
Ref: GSK | Image: GSK
